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Abstract: After publication of the results of the National Institute of Neurological Disorders 
and Stroke study, the application of intravenous thrombolysis for ischemic stroke was launched 
and has now been in use for more than 10 years. The approval of this drug represented only the 
first step of the therapeutic approach to this pathology. Despite proven efficacy, concerns remain 
regarding the safety of recombinant tissue-type plasminogen activator for acute ischemic stroke 
used in routine clinical practice. As a result, a small proportion of patients are currently treated 
with thrombolytic drugs. Several factors explain this situation: a limited therapeutic window, 
insufficient public knowledge of the warning signs for stroke, the small number of centers able 
to administer thrombolysis on a 24-hour basis and an excessive fear of hemorrhagic complica-
tions. The aim of this review is to explore the clinical efficacy of treatment with alteplase and 
consider the hemorrhagic risks.
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Introduction
Thromboembolic events can cause a wide range of diseases such as ischemic stroke or 
myocardial infarction. Removal of the obstructing clot was first attempted in myocardial 
infarction, which remains the only disease commonly treated with thrombolytic drugs. 
Although recombinant tissue-type plasminogen activator (rt-PA) has been approved 
for acute ischemic stroke, less than 5% of qualifying patients actually receive rt-PA.1 
In addition, rt-PA is the only drug licensed and available for treatment of ischemic 
stroke that can led to a recanalization of occluded vessels and to an improve in clinical 
outcome. The aim of this review is to report data on safety and efficacy of rt-PA in 
treatment of ischemic stroke.
Structure and mechanisms of action
Tissue plasminogen activator (t-PA) is an endogenous human serine protease found 
in the intravascular space, in the blood–brain interface, and in the brain parenchyma 
(neurons, astrocytes, and microglia).2,3 t-PA is composed by five conserved domains 
(finger, epidermal growth factor-like, K1, K2, and catalytic domain) that are differ-
ently involved in the pleiotropic functions of the molecule.4 t-PA plays a central role 
in maintaining homeostatic control in the blood coagulation cascade. By cleaving the 
precursor molecule plasminogen, it produces the active enzyme plasmin, which then 
dissolves fibrin-based clots in focal cerebral ischemia.
By contrast, in the brain parenchyma, t-PA has been associated with multiple 
physiologic and pathologic events including synaptic plasticity and cell death.Vascular Health and Risk Management 2009:5 398
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In pathologic conditions, t-PA has been linked to 
neurotoxicity (especially cell injury induced by activation 
of excitatory amino acid receptors). Like other molecules 
involved in central nervous system regulation, t-PA is 
produced by neurons (but also by glial cells), released 
through exocytocit mechanisms which is antagonized by 
neuroserpin.5 It may thus be classified as a neuromodulator6 
and its functions may include facilitation of axon elongation 
(by degradation of the extracellular matrix) and long-term 
potentiation of memory (LPT). This latter effect seems to 
be related to potentiation of glutamate (n-methyl-d-aspartic 
acid [NMDA]) receptor signaling and, more specifically, to 
the ability to cleave the NR1 subunit of the NMDA receptor, 
resulting in enhanced Ca2+ influx into the neuron. Moreover, 
the degradation of the extracellular matrix by t-PA seems to 
have a role in the physiological effect of t-PA on LTP.7
There is considerable release of endogenous t-PA in 
animal models of stroke, leading to incoordinate effects on 
NMDA receptor signaling and on the extracellular matrix. 
Thus, the physiologic effects of t-PA may become deleterious 
in the setting of cerebral ischemia.7 In particular the cleavage 
of the NR1 subunit of the NMDA receptor seems to play an 
essential mechanism in NMDA neurotoxicity.8
Likewise, destructive effects on the extracellular matrix 
and the endothelial basal lamina would explain the finding 
that rt-PA can compromise the integrity of the blood–brain 
barrier (BBB) and finally cause overt hemorrhage (see below, 
Hemorrhagic complication). This has been explored at 
molecular level in animal models5,9,10 and may be a decisive 
factor in the risk of symptomatic intracerebral hemorrhage 
(sICH) in patients treated with rt-PA.11 Of course, a central 
factor for the propensity of rt-PA to cause intracerebral 
hemorrhage (ICH) may be its ability to cross the BBB 
by virtue of its proteolytic activity, as observed in animal 
studies.5
Efficacy of intravenous thrombolysis
In 1995, the National Institute of Neurological Disorders and 
Stroke (NINDS) study group reported that patients with acute 
ischemic stroke who received alteplase (0.9 mg per kilogram 
of body weight, maximum dose 90 mg, 10% given as a bolus 
with the remainder given over one hour) within three hours 
after the onset of symptoms were at least 30% more likely 
to have minimal or no disability at three months than those 
who received placebo.12 A subsequent study demonstrated 
that patients treated with rt-PA were also more likely to 
have minimal or no disability at one-year follow-up.13 One 
year after the publication of the NINDS study, the US Food 
and Drug Administration approved intravenous rt-PA as a 
treatment for acute ischemic stroke and this treatment is the 
only approved medical therapy for patients with acute isch-
emic stroke to date and is recommended as first-line treatment 
by most national and international stroke associations.14–16
The widespread adoption of treatment with rt-PA has 
not been without controversy, at least in part because other 
studies with rt-PA in ischemic stroke have been negative, 
because of concerns that baseline imbalances in the NINDS 
report might explain the benefit of this treatment, and because 
the overall benefit in the trial included a 10-fold increase in 
the proportion of patients treated with alteplase suffering 
from sICH (6.4% versus 0.6% in the placebo group), which 
could compromise the benefit when used in routine clinical 
practice.
Negative thrombolytic studies differed from the NINDS 
trial in fundamental and important aspects, such as different 
thrombolytic drugs, different doses of rt-PA, and longer 
intervals between symptom onset and treatment. Among 
negative trials of intravenous rt-PA there was the first Euro-
pean Cooperative Acute Stroke Study (ECASS I), in which a 
higher dose of rt-PA was used and patients were randomized 
up to six hours after the onset of symptoms.17 In the ECASS II 
trial, the dose of rt-PA was identical to that used in the NINDS 
trial, but there was a six-hour treatment window, with most 
patients treated after three hours. In this second trial, the 
results were not in favor of treatment with alteplase.18
The Alteplase Thrombolysis for Acute Non-interventional 
Therapy in Ischemic Stroke (ATLANTIS) study used a 
treatment protocol identical to that of the NINDS trial but 
randomized patients from three to five hours after stroke and 
also showed negative results.19
Despite these findings, Hacke and colleagues reported 
positive results of an intention-to-treat analysis of pooled data 
from randomized trials of rt-PA for ischemic stroke (NINDS, 
ECASS I, ECASS II, and ATLANTIS) that included 
2775 patients treated up to six hours after symptom onset in 
more than 300 hospitals located in 18 countries (Table 1).20
This analysis supported the results of the NINDS trial 
and demonstrated that treatment within three hours (and 
possibly up to 4.5 hours) of symptom onset is associated with 
a greater chance of a favorable outcome at three months. This 
pooled analysis also showed how crucial the time of treat-
ment is; in particular, alteplase is nearly twice as efficacious 
when administered within the first 1.5 hours after the onset 
of ischemic stroke as it is when administered within 1.5 to 
3 hours after stroke onset (odds ratio for good outcome: 2.81 
for an interval of 0 to 90 minutes, 1.55 for 91 to 180 minutes, Vascular Health and Risk Management 2009:5 399
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and 1.40 for 181 to 270 minutes). Moreover, the estimated 
number needed-to-treat (NNT) of patients to identify clinical 
benefit is only three.21
The second concern about alteplase in clinical practice 
was that the baseline imbalance in stroke severity between 
the rt-PA- and placebo-treated groups in the NINDS trial 
might explain the benefit observed in clinical outcome. An 
independent group reanalyzed the trial data and confirmed 
a statistically significant treatment benefit despite subgroup 
imbalances in stroke severity assessed with National Insti-
tutes of Health Stroke Survey (NIHSS) score.22
Finally, we doubt the possibility that the results reached 
in the NINDS trial would be generalizable to nonstudy 
settings. This fear was reinforced by several observational 
studies that documented higher rates of bleeding complica-
tions occurring when treatment protocols were violated. In 
contrast, other observational studies reported that, in the “real 
world,” results similar to those found in the NINDS trial 
could be achieved only if treatment protocols were carefully 
followed.23 Moreover, a great number of studies asserted 
that successful clinical outcomes and low complication rates 
could be achieved by treating patients with intravenous rt-PA 
beyond the clinical trial setting.24–27 In particular, the Stan-
dard Treatment with Alteplase to Reverse Stroke (STARS) 
study conducted on consecutive acute stroke patients treated 
with intravenous rt-PA showed results similar to the NINDS 
study: 13.1% of patients died within 30 days of follow-up 
and 11.5% experienced an ICH.24
On the basis of these different results the European 
Medicines Agency (EMEA) granted approval of alteplase 
in 2002 under condition that a study be initiated in order 
to assess the safety and efficacy of rt-PA in routine clinical 
practice; subsequently, the Safe Implementation of Throm-
bolysis in Stroke–Monitoring Study (SITS-MOST) was 
undertaken.
SITS-MOST completed in 2007 and confirmed that 
alteplase is safe and effective when used in the first three 
hours after the onset of stroke in a wide range of clinical 
settings.28 The primary aim of the study was to establish 
whether the levels of safety seen in randomized controlled 
trial populations could be reproduced in routine clinical 
practice, and mainly concerned ICH. The results of this 
observational study showed that the proportion of patients 
who experience sICH was similar to that observed in 
randomized controlled trials. Moreover there was a trend 
towards a reduced incidence of ICH in SITS-MOST when 
compared to NINDS study, although confidence intervals 
(CI) overlapped. A reduction in mortality within the first 
three months was also seen in SITS-MOST compared with 
randomized controlled trials (11.3% vs 17.3%; 95% CI 
10.5–12.1, 14.1–21.1, respectively). This study was com-
pared with the Canadian Alteplase for Stroke Effectiveness 
Study (CASES), an observational cohort study on alteplase 
in ischemic stroke done between February 1999, and June 
2001, where mortality was 22.3%.29 Lower mortality in 
SITS-MOST could be explained with lower stroke severity 
and lower age in study population in respect to randomized 
controlled trials and CASES.
Similar results were achieved by smaller observational 
multicenter studies, including a total of about 650 patients,24,27 
although one case had a higher rate of sICH.30
Moreover the results of SITS-MOST regarding com-
plete recovery at three months follow-up was the same as 
in the pooled randomized controlled trials (39% vs 42% 
CI 36.9–39.7, 38.2–43.2, respectively).
Lyden and colleagues31 discussed the uncertainty shown 
by less experienced centers in including thrombolysis in their 
routine clinical practice. At the end of SITS-MOST study, 
the recruitment of “no-expertise” centers had increased to 
about 50%, thus demonstrating an increase in awareness 
Table 1 Results of major trials on use of endovenous rt-PA. Report of the 90-day outcome for patients treated with alteplase
Name of study  Treatment window  sICH  Mortality at  
three months
Independence 
at three months
NiNDS 3 hours 10.9% 17% 47.2%
SiTS-MOST 3 hours 7.3% 11.3% 54.8%
eCASS i 6 hours 24.9% 22.3% 41.6%
eCASS ii 6 hours 8.5% 10% 40.3%
ATLANTiS 3–5 hours 6.9% 17.3% 34%
eCASS iii 3–4.5 hours 2.4% 7.7% 52.4%
Abbreviations: ATLANTiS, Alteplase Thrombolysis for Acute Non-interventional Therapy in ischemic Stroke; eCASS, european Cooperative Acute Stroke Study; NiNDS, 
National institute of Neurological Disorders and Stroke; rt-PA, tissue plasminogen activator; siCH, symptomatic intracerebral hemorrhage; SiTS-MOST, Safe implementation 
of Thrombolysis in Stroke-Monitoring Study. Vascular Health and Risk Management 2009:5 400
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and growth in the ability to provide thrombolysis within the 
three-hour therapeutic window in clinical practice. Moreover, 
compared with centers with more experience, sICH was 
almost the same, which demonstrates that treatment safety 
could be maintained across all centers. Neither the proportion 
of patients with sICH nor the degree of independence at three 
months was significantly different between experienced and 
new centers. Mortality was a little higher in new centers but 
remained lower than that seen previously in randomized con-
trolled trials. This data could be explained by higher stroke 
severity in new centers (one point higher median NIHSS 
score) than in experienced centers.
It is interesting to note that there has been a gradual 
decline in the overall initial severity of stroke and in mortality 
rates among patients enrolled in major randomized studies 
of acute ischemic stroke over the past two decades. This 
observation may reflect the trend toward the use of alteplase 
in patients who have less severe neurologic impairments 
(as demonstrated by the results of the SITS-MOST trial), as 
well as the increased number of stroke units in Europe and 
the improved care provided by such units.
Thrombolysis after three hours
The second request of the EMEA was the initiation of a 
third randomized trial, ECASS III, in which the therapeutic 
window was extended beyond three hours. Before ECASS III, 
two European trials, the ECASS I and ECASS II, investigated 
a larger time window (up to six hours) but failed to show 
efficacy of treatment with alteplase.17,18 A subsequent analysis 
of the NINDS study32 and the combined analysis20 of data 
from the six randomized trials,12,17–19,33 showed a significant 
association between efficacy of treatment and the interval 
between the onset of symptoms and drug administration. 
Data from the pooled analysis showed a favorable outcome 
even if treatment was given between 3 and 4.5 hours, with an 
odds ratio of 1.4 for a good outcome with alteplase treatment 
as compared with placebo. This analysis also suggested that 
a longer time window was not associated with higher rates 
of sICH or with greater mortality.20
ECASS III is the second randomized trial (after the 
NINDS trial in 1995) to show significant treatment efficacy 
with intravenous alteplase in the unadjusted analysis of the 
primary end-point demonstrating that patients with acute 
ischemic stroke benefited from treatment when administered 
3 to 4.5 hours after the onset of stroke symptoms.34 Moreover 
this benefit was maintained as significant after adjustment for 
all prognostic baseline characteristics. In this trial the overall 
rate of sICH was increased in patient treated with rt-PA as 
compared with placebo, but mortality was not affected. All 
these findings are consistent with results from other random-
ized controlled trials.12,20,35
Finally, the initial severity of stroke represented the most 
predictive factor for the functional and neurologic outcome 
and for the risk of death. Previous trials failed to show a 
significant advantage of alteplase therapy in patients who 
received treatment within 0 to 6 hours after the onset of 
symptoms.18,19,36 It is likely that the time window of up to six 
hours and the lack of statistical power are responsible for the 
failure of these studies.
Although it is well known that thrombolysis for ischemic 
stroke is associated with an increased risk of symptomatic 
intracranial hemorrhage, it is difficult to compare the inci-
dence of this complication in the various studies due to the 
different definitions used for intracranial hemorrhage.
The classifications widely used in clinical trials to identify 
intracranial bleeding are those reported in the NINDS and 
ECASS studies.12,17,18 In the former, hemorrhagic transfor-
mations were divided into two radiological groups: hemor-
rhagic cerebral transformation and intracerebral hematomas. 
Hemorrhagic cerebral infarction is defined as computed 
tomography (CT) findings of acute infarction with punctate or 
variable hypodensity/hyperdensity with an indistinct border 
within the vascular territory suggested by acute neurologic 
signs and symptoms. Intracerebral hematoma is defined as 
a typical homogeneous, hyperdense lesion with a sharp bor-
der with or without edema or mass effect within the brain. 
This hyperdense lesion could arise at a site remote from the 
vascular territory of the ischemic stroke or within but not 
necessarily limited to the territory of the presenting ischemic 
stroke. Also hemorrhage with an intraventricular extension 
is considered an intracerebral hematoma.
ECASS classification is a purely radiological definition 
subdivided into four categories: hemorrhagic infarction 
type 1 (HI-1; small petechiae along the margins of the 
infarct); hemorrhagic infarction type 2 (HI-2; confluent pete-
chiae within the infracted area, but without space-occupying 
effect); parenchymal hematoma type 1 (PH-1; an hematoma 
in less than 30% of infracted area with some slight space-
occupying effect); parenchymal hematoma type 2 (PH-2; 
a dense hematoma in more than 30% of infarcted area with 
substantial space-occupying effect, or any hemorrhagic lesion 
outside the infarcted area).
In the ECASS III trial, sICHs have been identified as the 
predominant cause of neurologic deterioration. Considering 
this definition, a difference of 2.14% was found between the 
two treatment arms. The authors also analyzed the incidence Vascular Health and Risk Management 2009:5 401
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of intracranial hemorrhage using the definition of the other 
trials12,17,37 and in this case the rate of sICH was no higher 
than that reported in previous trials or in SITS-MOST, despite 
the extended time window.
In ECASS III the overall mortality rate was approximately 
8% and was lower than that reported in previous trials and this 
fact could be also attributable to the inclusion of patient with 
lower stroke severity (baseline NIHSS score: for ECAS-III, 
9; for NINDS, 14).
In comparison with pooled analysis of previous random-
ized trials, in ECASS III, the odds ratio for a good outcome 
was 1.34 (CI 181–270 minutes) and the NNT for a good 
outcome is equal to 14. The effectiveness of alteplase in 
an extended time window up to 4.5 hours is confirmed by 
evaluation of the data from the Safe Implementation of 
Thrombolysis in Stroke–International Stroke Thrombolysis 
Register (SITS-ISTR) registry which shows that the rates of 
sICH, mortality, and independence at three-month follow-
up in routine clinical practice are similar in patients who 
received treatment between three and 4.5 hours and for those 
treated within three hours from stroke onset.38 In the SITS-
ISTR registry, a small group of patients (n = 664) received 
rt-PA after three hours. In the three to four, five-hour cohort, 
any hemorrhage occurred in 17% of patients whereas 8% 
had symptomatic intracranial bleeding according to the 
NINDS definition. Moreover 41% of patients reached a 
score of 0–1 on the modified Rankin score at three months 
follow-up. The results of both studies (SITS-ISTR and 
ECASS III) are statistically significant and allow physicians 
to extend the window of treatment up to 4.5 hours.
Intra-arterial and combined 
thrombolysis
Different strategies for treating acute ischemic stroke have 
included primary intra-arterial (IA) therapy, as reported 
in several case series and the Prolyse in Acute Cerebral 
Thromboembolism (PROACT) trials,39–41 and combined 
intravenous/IA therapy.42–47
In these studies, neurological improvement was variable 
with minimal or no neurological deficit reported in 15% to 
75% of patients. Factors affecting this wide variation in 
outcome are represented by the system used for assessing out-
come, the dose of thrombolytic agent used, the differences in 
baseline patient characteristics (mainly age and neurological 
impairment at baseline) and the site of arterial occlusion. 
In these reports, time from stroke onset is up to six hours 
with complete recanalization seen in approximately 40% of 
patients and partial recanalization in 35%.40,48–51 In this report, 
the rate of recanalization was higher than in other studies 
with intravenous rt-PA.52
The PROACT I and II trials assessed the safety and 
efficacy of IA thrombolysis.39,40 In PROACT I,39 stroke 
patients presenting within six hours of symptom onset with 
angiographically proven middle cerebral artery (MCA) 
occlusion were enrolled. Subjects were randomized at 
prourokinase or placebo over 120 minutes into the proximal 
thrombus face. Partial or complete recanalization was 
obtained in 57.7% of patients treated with prourokinase, 
whereas hemorrhagic transformation, causing neurologic 
deterioration within 24 hours, occurred in 15.4% of cases. 
However, the number of patients enrolled in this study was 
too small to reach a statistical significance in clinical out-
come, so the PROACT II, a larger, randomized study was 
started. Also this latter study supported previous reports 
showing a higher degree of arterial recanalization and a 
better outcome in patients who underwent IA fibrinolysis 
compared to placebo group.40
All randomized trials were performed in patients with 
anterior circulation ischemic stroke; this is mainly due to 
the greater severity and clinical difference of stroke in the 
vertebrobasilar system. The clinical outcome of patients with 
vertebrobasilar occlusion seems to be less favorable with 
higher reported morbidity and mortality,53 and reports on 
the natural history of stroke in posterior circulation shows a 
global poor outcome with mortality in up to 80% of cases.54–57 
In addition, the evolution of clinical signs in posterior circula-
tion stroke differs from those in anterior circulation stroke. 
In the latter, onset of symptoms is often concomitant with 
abrupt occlusion of the vessel whereas in the former there 
often may be a gradual evolution of symptoms.58 Patients 
with vertebrobasilar infarcts are more prone to have severe 
intracranial large-artery disease which can led to restenosis 
after thrombolysis.59–61
There are only a few reports about intra-arterial throm-
bolysis in posterior circulation and most extended the time 
of intervention beyond six hours.61 No randomized trials 
evaluated the safety and efficacy of intra-arterial or endove-
nous fibrinolysis in vertebrobasilar stroke but, as the natural 
history of this type of stroke is severe, a neurointerventional 
approach could be the only lifesaving therapy to show some 
benefit in patients.
The intravenous administration of rt-PA has the advan-
tage of early treatment initiation, but it is limited by poor 
recanalization rates with 30% to 40% of major occluded 
arteries that partially or completely recanalize as evaluated 
by cerebral angiography.52Vascular Health and Risk Management 2009:5 402
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The combination of intravenous rt-PA with local IA 
therapy may improve the chance of achieving a better 
recanalization rate by taking advantage of both treatments, 
and could increase clinical recovery as a result of early ini-
tiation of therapy and a hypothesized higher recanalization 
rate; however, this approach may increase the risk of sICH 
compared with either treatment alone.
The Interventional Management of Stroke (IMS) study42,62 
was performed using intravenous/IA rt-PA therapy. Patients 
with an NIHSS score of 10 at baseline had intravenous rt-PA 
initiated (0.6 mg/kg, 60 mg maximum over 30 minutes) 
within three hours of onset. Afterwards additional rt-PA was 
administered intra-arterially at the site of clot up to a total 
dose of 22 mg over two hours of infusion or until lysis of 
thrombus was obtained. The analysis of results was made by 
comparing patients who were treated with placebo or with 
intravenous rt-PA from the NINDS study. Patients treated 
with combined intravenous/IA rt-PA had a significant better 
outcome at three months follow-up compared with placebo 
arm patients in NINDS trial, while no significant difference 
was found in the rate of ICH when compared with patients 
in NINDS treated with rt-PA.
Another pilot study, the Emergency Management of 
Stroke (EMS) Bridging Trial was performed in order to 
evaluate safety and efficacy of combined therapy in patients 
with acute ischemic stroke.43 Although the study sample was 
small, an increased rate of recanalization was observed in 
the group treated with combined therapy when compared to 
patients treated with intra-arterial rt-PA alone.
In another report,63 despite the highest number of patients 
with type of vessel occlusion associated with poor prognosis 
(11 internal carotid artery, and five basilar artery) and a higher 
baseline NIHSS score in the intravenous/IA versus IA arm, 
patients in combined therapy showed a more favorable out-
come with comparable rates of mortality and numbers of sICH 
when compared to patients receiving IA therapy alone. There 
was a trend toward improved clinical outcome in patients 
receiving intravenous/IA therapy while safety was similar to 
that of IA therapy alone. The authors attributed this improve-
ment to earlier initiation of treatment, and greater recanali-
zation rates with combined intravenous/IA thrombolysis. 
Potential disadvantages of combined therapy may include 
higher total rt-PA doses which could contribute to increases 
in the rates of cerebral hemorrhagic transformation.
Hemorrhagic complication
The efficacy of thrombolysis for ischemic stroke has been 
confirmed since the publication of the NINDS study, but only 
1%–8% of potentially eligible patients are being treated in 
the United States and in Europe.64
Several factors have been reported to explain the underuse 
of this therapeutic approach to ischemic stroke: the short ther-
apeutic window, insufficient public warning and knowledge 
of stroke symptoms, the limited number of centers able to 
perform thrombolysis on a 24-hour basis and an excessive 
fear of hemorrhagic complications.65
Although in clinical practice this complication may be 
less frequent than failure of treatment to recanalized occluded 
cerebral artery or early (up to 48 hours) reocclusion, ICH 
seems to represent an important obstacle to the generalization 
of thrombolytic therapy.
Intracerebral hemorrhage mostly occurs in the core of 
the infracted area, thus suggesting that ischemic events can 
have an important role.37 An hemorrhagic transformation 
can happen spontaneously and sometimes during the early 
hours of a cerebral infarction. This hemorrhagic risk is clearly 
increased by administration of an heparin or thrombolytic 
agent. As reported before, the principal requisition for blood 
extravasation towards the brain tissue is an alteration of the 
BBB.11 In experimental models of focal cerebral ischemia, 
the basal lamina of the vessels and the extracellular matrix 
show an alteration and the adhesion between the microvessel 
cells and the extracellular matrix is dearranged so there can 
be an extravasation of blood elements. There is an increase 
in capillary permeability that comes along with an inrush 
of plasma components inside the brain tissue, an inflamma-
tory reaction with thrombin activation, and an increasing 
of many mediators such as platelet-activating factor, tumor 
necrosis factor α and bradykinin, which contribute to increase 
endothelial permeability. In addition, oxidative damage may 
increase hemorrhagic risk.66
Matrix metalloproteinases (MMP) are involved in the 
hemorrhagic transformation, and their activation is partly 
responsible for the BBB disruption. MMPs represent a 
family of proteolytic enzymes combined with zinc, which 
acts normally on the remodeling of the extracellular matrix. 
Inappropriate activation can induce proteolysis of the 
matrix of the neurovascular unity (endothelium, astrocyte, 
and neuron). MMPs are liberated by the endothelium and 
the polynucleates at the inflammatory stage of ischemia 
and utilize type IV collagen and laminin as substrates. In 
some animal models of focal cerebral ischemia, activation 
of MMP-9 is associated with increased permeability of 
the BBB that leads to edema formation and hemorrhagic 
transformation.67–70 In some studies, a complementary role 
of plasmin (which is another serine-protease generated by Vascular Health and Risk Management 2009:5 403
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interaction between t-PA and the thrombus) is observed in 
the disruption of the BBB and the occurrence of ICH.71
MMP-2 and MMP-9 released during the ischemic event 
can damage the vessel components, particularly type IV 
collagen, fibronectin, and laminin, thus altering the basal 
lamina of the cerebral vessels. In humans, elevation of 
MMP-9 is linked to the severity of ischemic stroke,72 and 
the pretherapeutic MMP-9 rate is an independent predictor 
of the risk of hemorrhagic transformation related to throm-
bolysis.73,74 The importance of plasma levels of MMP-9 has 
to be clarified to determine if evaluation of pretreatment 
MMP-9 levels is likely to improve the benefit–risk ratio of 
rt-PA administration for stroke in routine use. Moreover the 
association of a nonspecific inhibitor of MMPs (BB-94) with 
rt-PA is able to limit the frequency of hemorrhagic transfor-
mation without diminishing lytic efficiency.75
Also plasma elevation of cellular fibronectin (cFN), a 
substance synthesized by endothelial cells that reflects micro-
vascular damage, is considered a marker of t-PA-related ICH 
probably more specific than MMP-9 concentration.76
Preliminary studies have also suggested that there are 
many other biomarkers that may be able to predict the risk 
of ICH. Pretreatment levels of endogenous fibrinolysis 
inhibitors (plasminogen activator inhibitor [PAI-1] and 
thrombin-activated fibrinolysis inhibitor [TAFI]) could 
predict rt-PA-related sICH.77 Exact knowledge of mecha-
nisms related to ICH after thrombolysis and the role of 
biomarkers could be useful in selecting patients that can 
benefit from such treatment. Other elements must be taken 
in account for the genesis of rt-PA-related ICH: age, hyper-
tension, diabetes mellitus or cerebral amyloid angiopathy, 
extent of early ischemic signs shown on brain CT scan or the 
volume of cerebral ischemic lesions on diffusion weighted 
MRI, and the presence of leukoaraiosis.17,78–80
In the NINDS t-PA Stroke Study, as well as in some 
meta-analyses, sICH was defined as a CT-documented 
hemorrhage that was temporally related to any deterioration 
in the patient’s clinical condition.37 The post-thrombolysis 
ICH spectrum ranges from frequent benign hemorrhagic 
petechiae that can be associated with early reperfusion, to rare 
large parenchymal hematomas with severe mass effect.
Analysis from the ECASS I and ECASS II studies 
showed that only the PH-2 type parenchymal hematomas 
(homogeneous hematomas with mass effect occupying 30% 
of ischemic lesion volume) are associated independently with 
clinical deterioration and poor prognosis.81,82
Longer door-to-needle time has been shown to be 
associated with higher rates of sICH.83 However, the majority 
of  studies have not identified the time to onset of thrombolytic 
treatment as an independent risk factor of sICH in multi-
variate analysis, and the pooled analysis of the NINDS, 
ECASS, and ATLANTIS trials failed to show an independent 
association between timing of rt-PA administration and risk 
of cerebral hematoma.20
The first trials on rt-PA have provided evidence that 
higher doses of lytic agents lead to higher rates of sICH,17,84 
so the dose was limited to 0.9 mg/kg up to 90 mg in total.
Age has been consistently found to be a risk factor for 
sICH after thrombolysis for both acute ischemic stroke 
and myocardial infarction.79,80,86 In the ECASS I study, age 
is the only independent predictive factor of parenchymal 
hematomas, with an odds ratio of 1.3 for every 10 year 
increase in age.17 Higher hemorrhagic risk could be linked 
to high frequency of microangiopathic processes, especially 
cerebral amyloid angiopathy in elderly patients and to the 
presence of leucoaraiosis.87 In the study by Heuschmann and 
colleagues, the rate of sICH increased with age from 4.9% 
in patients younger than 55 years to 10.3% in patients aged 
75 years and older.88 In some European countries, rt-PA is 
not recommended as treatment of ischemic stroke in patients 
older than 80 years. Recent data from several open-label 
studies on use of rt-PA have shown that the risk of sICH in 
the elderly is comparable to that of younger patients.89–91 In 
particular the CASES trial showed that the benefit–risk ratio 
of intravenous rt-PA can be favorable in carefully selected 
elderly stroke patients treated within three hours.91 The 
sICH rate was 4.4% in the group of patients aged 80 years 
or older included in this study. The Stroke Survey Group 
rt-PA analysis also concluded that it was not justified to 
systematically contraindicate thrombolysis for patients older 
than 80 years.89
Many authors have shown the importance of the baseline 
stroke severity in hemorrhagic risk after thrombolysis.12,78,85,92 
In the NINDS study, patients with a baseline NIHSS score of 
20 were 11 times more prone to having sICH than patients 
with an NIHSS score of 5.12 The Multicentre tPA Acute 
Stroke Survey study also showed that the NIHSS score was 
an independent marker of ICH, with an odds ratio of 1.38 
for a one-point increase in the NIHSS score.89 On the basis 
of these results, in some countries a NIHSS score of 25 
represents a contraindication for alteplase administration. 
In contrast to the NINDS study, Sylaja and colleagues on 
their report did not find a significant association of severity 
of neurological deficit at baseline with increased risk of 
sICH.91 Moreover, the ECASS I trial showed that severity 
of neurological deficit at admission represented a risk factor Vascular Health and Risk Management 2009:5 404
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for hemorrhagic transformation and not for parenchymal 
hematoma.79
Another factor which may contribute to the development 
of rt-PA-related sICH is hypertension during the first 24 hours 
after ischemic stroke;78 this data underlies the importance of 
close surveillance of blood pressure during the first 24 hours 
and the benefit of applying a strict therapeutic protocol for 
the control of hypertension, similar to the one used by the 
NINDS study, to limit hemorrhagic risk.
It is well known that patients with hyperglycemia have 
worse outcomes when compared to those with normal blood 
glucose on presentation.93 Experimental and human studies 
indicate that hyperglycemia predicts higher stroke mortality 
independently from stroke severity, stroke type, or age. These 
data suggest that hyperglycemia may directly contribute to 
poor outcomes by exacerbating acute brain injury.94–96 Alter-
natively, it has been proposed that hyperglycemia is simply 
a bystander phenomenon, a catecholamine-based stress 
response to a more severe stroke, which may not have any 
direct causative role in the poor prognosis that is observed 
among these patients.97–99
Moreover several studies have shown the influence of 
baseline glycemia on the risk of ICH after thrombolysis.85,100,101 
In a study published in 1999, patients with a glycemia value 
of 200 mg/dl on admission showed a symptomatic hema-
toma rate of 25% after treatment by t-PA.100 In the PROACT 
II study, there was an increased risk of sICH in patients with 
pretherapeutic glycemia higher than 200 mg/dl.102
The mechanism of hyperglycemia-related ICH is not 
clear. There are numerous animal experimental proofs that 
hyperglycemia provokes microvascular lesions as well as 
BBB damage, leading to hemorrhagic transformation of 
the cerebral infarction.103 Moreover Sylaja and colleagues91 
did not find that a history of diabetes mellitus was a risk 
factor for sICH, despite the fact that many patients with 
diabetes mellitus had elevated serum glucose at stroke onset. 
This may be due to the fact that it is the baseline glucose 
level, not diabetes mellitus per se, which is predictive 
of ICH.100
The deleterious effect of rt-PA attributed to MMPs wors-
ened in the presence of hyperglycemia and a glycemia value 
above 400 mg/dl represents a contraindication to cerebral 
thrombolysis by intravenous t-PA.
The significance of early ischemic changes on baseline 
brain CT scan as predictors of hemorrhagic transforma-
tion scan remains controversial.104,105 The ECASS I and 
ECASS II trials have shown that the presence of early isch-
emic change in more than one-third of the MCA territory 
before thrombolysis is accompanied by an increase in the 
hemorrhagic transformation risk and poor clinical outcome. 
In a paper by Tanne and colleagues, the symptomatic ICH rate 
is multiplied by more than four in patients with such signs on 
CT.85 In contrast, other studies on thrombolysis have shown 
that the presence of ischemic change in CT scan is related 
to stroke severity but is not independently associated with 
the occurrence of ICH.106,107
One concern regards the sensitivity and reproducibility of 
early ischemic change detection that depend on the quality 
of the CT scanner used and on the experience of the reader. 
Interobserver reproducibility can be improved by a standard-
ized reading of the CT scan according to the Alberta Stroke 
Program Early CT Score (ASPECTS) score.107
A recent retrospective multicenter study evaluated 
whether leukoaraiosis is a risk factor for sICH in patients 
treated with alteplase (endovenous or IA) for anterior 
circulation stroke.108 All patients had received magnetic 
resonance imaging (MRI) evaluation before thrombolysis 
and for statistical analysis. Leukoaraiosis in the deep 
white matter was dichotomized into absent or mild versus 
moderate or severe. The rate of sICH was significantly 
higher in patients with moderate to severe leukoaraiosis than 
in patients without relevant leukoaraiosis (10.5% vs 3.8%; 
p  0.005), with an odds ratio of 2.9. In the logistic regres-
sion analysis (including age, NIHSS score on admission, and 
type of thrombolytic treatment), leukoaraiosis remained an 
independent risk factor.
The risk of ICH after thrombolysis in ischemic stroke 
patients carrying old asymptomatic microbleeds (which can 
considered as a marker of microangiopathy, and of amyloid 
angiopathy remains a controversial subject.109–112 Only few 
studies have performed pretherapeutic T2* MRI sequences 
to evaluate the presence of microbleeds and their influence 
on ICH risk.
Two case series112,113 reported the same (18% and 
16%, respectively) incidence of some microbleeds on the 
pretherapeutic T2* MRI sequence. In both cases none of the 
patients treated with alteplase experienced sICH. Moreover, 
in a recently published pooled analysis of 570 patients, the 
presence of microbleeds (detected in 86 patients) was not 
predictive of sICH after thrombolysis.114 This limited data 
does not support the exclusion from thrombolysis of stroke 
patients carrying a few microbleeds on pretherapeutic T2* 
sequences.
Some authors have suggested that the differences 
between symptomatic and asymptomatic ICHs are due 
to the intensity of bleeding rather than physiopathologic Vascular Health and Risk Management 2009:5 405
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differences. For others, hemorrhagic infarctions and 
parenchymal hematomas after t-PA have a different clinical, 
etiologic, and biological significance.115 Benign hemorrhagic 
transformation can be associated with the natural history 
of ischemic stroke while parenchymal hematomas, espe-
cially the PH-2 type, could be linked to the t-PA itself and 
particularly to its impact on homeostasis (as demonstrated 
by elevation of fibrin degradation products [FDP] after 
treatment).116
Adherence to the inclusion criteria of the NINDS trial 
represents a key point for a favorable benefit–risk ratio in the 
routinely administration of alteplase for ischemic stroke.
However, these inclusion criteria are more than 10 years 
old and can appear obsolete as they do not take into account 
the development of new diagnostic tools. In particular the 
development of new MRI sequences and the identification 
of the new biomarkers (MMP-9, PAI-1, TAFI, and cFN) can 
be useful in assess the benefit–risk ratio.
A recent multicenter study compared the clinical evolu-
tion of patients selected on the basis of MRI and treated 
by intravenous t-PA within the first six hours to that of 
patients included in the ATLANTIS, ECASS, and NINDS 
studies.117 Patients without significant perfusion–diffusion 
mismatch and patients with an extended lesion on the diffu-
sion sequence (50% of the MCA territory) were not treated 
with alteplase. In the group of patients selected on the basis 
of MRI, the rate of sICH was significantly lower (3% vs 
8%; p = 0.01) and a favorable outcome could be achieved 
in 48%.
The same results were obtained in a recent study which 
evaluated the efficacy of thrombolysis treatment within and 
beyond the three-hour time window when the decision was 
based on MRI versus CT scan.118 Also in this report, even 
if treated after the three-hour window, when selected on the 
basis of MRI results, patients had a significantly lower risk 
than for sICH (3% vs 9%; p = 0.013) and lower mortality 
(12% vs 21%; p = 0.021) (Table 2).
Conclusion
The introduction of rt-PA in clinical practice for the treatment 
of acute ischemic stroke has represented an important step in 
the therapeutic approach to a difficult and once untreatable 
clinical condition. Its major complication, ICH, describes 
complex and heterogeneous groups of phenomenon, and 
involves multiple demographic, clinical, biological, and 
hemodynamic parameters, knowledge of which remains 
partial. Identification of the risk factors for sICH will help 
in improved selection of patients for thrombolysis.
The future of t-PA for the treatment of patients with acute 
ischemic stroke largely depends on successfully attaining 
several goals including: (i) a better organization of the health 
care system, (ii) improvement of the thrombolytic properties 
of t-PA, (iii) inhibition of the deleterious effects of t-PA on 
the permeability of the neurovascular unit without interfering 
with its thrombolytic properties, (iv) attenuation of the neuro-
toxic effects of t-PA, and (v) extension of the time window. 
The organization of the health care system should include 
educational programs directed to the public and the develop-
ment of dedicated acute stroke units staffed by personnel with 
expertise in the diagnosis and treatment of acute stroke.
The improvement of the efficiency of t-PA as a throm-
bolytic agent may be based on the results of ongoing studies 
which are testing the effect of combined intravenous and 
intra-arterial thrombolysis in addition to the simultaneous 
use of t-PA and transcranial or local procedures; among 
these is the EKOS 1-catheter-delivered ultrasound trial by 
EKOS Corporation.119
Moreover, because the effect of t-PA on the BBB 
permeability seems to be have an important role in the 
deleterious effects of t-PA itself in the ischemic brain, the 
Table 2 Risk factors for hemorrhagic transformation in acute ischemic stroke following thrombolysis
Clinical factors Biochemical markers Radiologic factors
Thrombolytic agent (dose, route of administration, 
time of onset to thrombolysis, type of agent)
elevated blood glucose early ischemic change on CT
Stroke severity elevated red cell count Large volume infarct, edema, or mass effect 
on the baseline CT
Advancing age elevated matrix metalloproteinase Presence of lacune
History of diabetes elevated calcium-binding proteins Reduced blood volume on Pwi
elevated blood pressure Early fibrinogen degradation coagulopathy Breakdown of blood–brain barrier
History of cardiac failure Presence of microbleeds on MRi
    Leukoariosis on MRi
Abbreviations: CT, computed tomography; MRi, magnetic resonance imaging; Pwi, perfusion-weighted image.Vascular Health and Risk Management 2009:5 406
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combined therapy of t-PA and protectors of the integrity of 
the neurovascular unit might achieve promising results. The 
targets of neuroprotective experiments have included calcium 
antagonists, sodium channel blockade, glutamate/NMDA 
antagonists, free radical scavengers, apoptosis inhibitors, 
γ-aminobutyric acid-A (GABAA) agonists, and agents that 
stabilize the neuronal membrane. Unfortunately almost all 
the trials conducted with such neuroprotective agents failed 
to shown a substantial benefit in ischemic stroke patients.
Based on the observation that the interaction of t-PA 
with the NMDA receptor occurs through a particular kringle 
domain,120 new t-PA muteins lacking this domain or contain-
ing mutations were developed with the aim to minimize the 
NMDA-receptor-dependent neurotoxic effects of alteplase 
to be less harmful when administered in ischemic stroke 
patients.
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